Patent Annuities: Multi-Country Renewal Fees

“Patent annuities” is the term used across most of the world — and universally inside the European Patent Office (EPO) system and the commercial patent-renewal-payment industry — for the recurring fees that keep a patent (or a pending patent application) in force. It describes the same underlying obligation as the U.S. term maintenance fee, but the vocabulary shift matters operationally: outside the United States, “annuity” is standard usage in patent-office fee schedules, renewal-service invoices, and docketing software, and the obligation it describes is structurally more complicated than a single country’s maintenance-fee schedule. A U.S. patent has one fee schedule, paid to one office, on three fixed dates. A patent family validated in fifteen countries has, potentially, fifteen separate annuity schedules — different due dates, different currencies, different grace periods, different local-agent requirements — all attached to what a university technology transfer office (TTO) still thinks of as a single invention.

This guide covers how patent annuities work mechanically, using the EPO as the primary worked example since it is the route most university-owned international patent families pass through, and then focuses on what is specific to institutional portfolio management: why annuities become an operational problem at multi-country scale in a way a single-jurisdiction maintenance-fee schedule does not, and how TTOs manage that. For the U.S.-specific maintenance-fee schedule and escalation curve, see CASRAI’s guide to how long patents last and to IP renewals, which covers USPTO maintenance fees and trademark renewals in detail; this page does not re-derive that material.

How patent annuities work at the EPO

Under the European Patent Convention, renewal fees (annuities) become due starting with the third year computed from the application’s filing date, and continue for as long as the application is pending or the resulting patent stays in force. While an application is still pending before the EPO, annuities are paid centrally to the EPO itself, and the fee escalates annually from the third year through roughly the tenth year before leveling off for the remaining years up to the 20-year statutory ceiling. As of the EPO’s fee schedule immediately prior to its April 2026 update, the third-year renewal fee stood at EUR 530, with each subsequent year’s fee higher than the last. The EPO raised most official fees, including annuities, by an average of roughly 5% effective 1 April 2026 — confirm the current amount against the EPO’s own published fee schedule before budgeting a specific payment, since official fees are revised periodically and a figure even a year old should not be relied on for an actual due payment.

What happens after grant is where the multi-country complexity actually starts, and it depends on which post-grant route the applicant takes:

Classic (non-unitary) European patent. Once granted, a European patent is not itself a single enforceable right — it must be validated in each individual EPC contracting state where protection is wanted, converting it into a bundle of separate national patents. From that point, the applicant stops paying the EPO and instead pays a separate renewal/annuity fee to each national patent office, at that country’s own rate, in its own currency, on its own due date, with its own grace period and (in most countries) a requirement to act through a local patent agent or representative.
Unitary Patent (UP). Since the Unitary Patent system took effect on 1 June 2023, an applicant can instead request unitary effect, which covers the participating EU member states under a single right with a single, centralized renewal fee paid to the EPO — collapsing what would otherwise be many separate national annuities into one payment. The UP does not cover every EPC state (several EPC members, including some major markets, are outside the UP system and still require separate national validation and annuities), so a portfolio holder pursuing broad European coverage may still end up paying a mix of one UP annuity plus several national annuities for the states the UP doesn’t reach.

Why this is a distinct problem for university TTOs

A U.S.-only patent portfolio has one fee schedule per asset, with three known payment dates over the life of the patent — a tractable tracking problem even at a few hundred assets. An internationally filed portfolio multiplies that by the number of countries in each patent family. A single invention that entered PCT national phase in ten countries generates, after grant, ten separate national annuity obligations (or, if some of those are UP-participating EU states validated as a Unitary Patent, one UP annuity plus however many remain outside it) — each on its own annual clock, denominated in a different currency, frequently requiring a local associate in that country to actually make the filing and payment. A TTO with even a modest number of internationally protected inventions can be tracking well over a hundred individual annuity due dates across a given year, each one an unrecoverable, high-consequence deadline if missed (a lapsed patent in a given country generally cannot be easily revived, and where revival exists at all it is a materially more expensive and uncertain path than paying on time). This is structurally the same failure mode CASRAI’s IP renewals guide describes for U.S. maintenance fees and trademark renewals — a deadline landing during a personnel transition, a spreadsheet cell nobody updated — just multiplied across as many national clocks as the portfolio has countries.

The maintain-or-abandon decision, at multi-country scale

Because annuities are charged per country and escalate with the age of the patent in every one of them, the maintain-or-abandon review that CASRAI’s IP renewals guide describes for a single U.S. asset becomes, for an internationally filed invention, a review that has to happen separately for every country in the family — and the right answer is very often not uniform across the family. It is common and often financially rational for a TTO to let annuities lapse in countries where a licensee has no manufacturing, sales, or field-of-use interest, while continuing to pay in the two or three countries where the actual commercial activity is happening, rather than treating the whole international family as a single maintain/abandon decision. Two points in the lifecycle concentrate that review in practice: PCT national-phase entry, around 30 months from the earliest priority date, is the decision point for how many and which countries to file in at all (see CASRAI’s PCT patent application guide for the national-phase timeline and costs), and each subsequent annuity due date in each country is a smaller, recurring version of the same question. Where a patent is subject to an active license, CASRAI’s patent licensing guide covers how licensee diligence and territory obligations should inform which national validations are worth keeping active, and where the invention originated from federal funding, the disclosure and commercialization-diligence expectations under the Bayh-Dole Act can bear on whether abandoning international protection is a decision the institution can make unilaterally.

Managing an international annuity portfolio

A few structural practices reduce the risk of a missed international annuity, beyond what a single-jurisdiction maintenance-fee tracker needs:

Dedicated annuity-tracking systems or services, not a shared calendar. Most institutions with any meaningful international filing footprint either use IP docketing software built to track multi-country renewal schedules natively, or delegate payment and local-agent coordination entirely to a commercial patent-annuity payment service that specializes in exactly this — paying the right national office, in the right currency, through the right local associate, on the right date, across dozens of jurisdictions at once. At true multi-country scale this is less a convenience than a control: the number of independently-clocked deadlines exceeds what manual tracking reliably catches.
A documented per-country review, not a per-family default. Build the maintain-or-abandon question into the docketing workflow at the country level, not just the invention level, so that a family with real commercial activity in three countries and none in seven doesn’t default to renewing (or abandoning) all ten together.
Lead time that accounts for local agents. Many national offices require payment or an accompanying filing through a locally admitted patent agent, which adds a coordination step a purely domestic renewal doesn’t have — deadlines need enough lead time (commonly several months) for that coordination to happen before a grace period is the only option left.
Budgeting for currency and escalation together. International annuity costs move with both the fee-escalation curve in each country and exchange-rate fluctuation across the portfolio’s currencies — a portfolio-level annuity budget built on a single prior-year total will understate cost growth from either source.

Frequently asked questions

Are “patent annuities” and “patent maintenance fees” the same thing?

Functionally yes — both describe the recurring payments required to keep a patent (or pending application) in force. “Maintenance fee” is the term used specifically in U.S. practice and by the USPTO; “annuity” is the term used at the EPO, in most other national patent offices, and throughout the commercial patent-renewal-payment industry that serves international portfolios.

Do all countries charge patent annuities?

No single global rule applies. Most major patent offices, including the EPO and the great majority of its member states, charge annuities on a defined schedule. A small number of jurisdictions handle renewal differently or not at all for certain patent types (for example, U.S. design and plant patents require no maintenance fee under 35 U.S.C. § 41(b), unlike U.S. utility patents). Always confirm the specific renewal regime for each country in a patent family rather than assuming uniformity.

What happens if an annuity payment is missed in one country?

Most national offices provide a grace period after the due date, typically with a late-payment surcharge, after which the patent lapses in that country specifically — it does not affect the patent’s status in other countries where it was separately validated. Reviving a lapsed patent, where revival is available at all, is a materially more expensive and uncertain process than paying on time, and in many jurisdictions is not available at all once the grace period has passed.

Should a university TTO use a commercial annuity payment service for an international portfolio?

Many do, specifically because the number of independently-clocked national deadlines in even a moderately sized international portfolio exceeds what in-house tracking reliably catches, and because these services already maintain the local-agent relationships each country’s payment requires. Whether it makes sense for a given institution depends on portfolio size and how many countries are actually represented across the family of assets — a portfolio validated in one or two countries per invention may not need it, while one with routine ten-plus-country validations usually benefits from it.

Patent Annuities: Managing Renewal Fees Across a Multi-Country Patent Portfolio